Developing the future oncology specialist
After completing the 12-month PGY-2 Pharmacy Residency in Oncology at Mayo Clinic Hospital — Rochester, you will be a proficient independent practitioner capable of providing advanced pharmaceutical care to oncology patients.
The purpose of the PGY-2 Pharmacy Residency in Oncology at Mayo Clinic Hospital — Rochester is to build on Doctor of Pharmacy (Pharm.D.) education and PGY-1 pharmacy residency programs to contribute to the development of clinical pharmacists in specialized areas of practice. PGY-2 residencies provide you with opportunities to function independently as a practitioner by conceptualizing and integrating accumulated experience and knowledge and incorporating both into the provision of patient care or other advanced practice settings.
Residents who successfully complete an accredited PGY-2 pharmacy residency are prepared for advanced patient care, academic, or other specialized positions, along with board certification, if available.
The program provides the high-quality didactic and clinical experiences needed to create a well-rounded, fully competent oncology pharmacist. PGY-2 oncology pharmacy residents:
- Develop expertise, knowledge and skills in oncology therapies
- Contribute to an interdisciplinary health care team offering patient-specific therapeutic interventions to treat, cure, rehabilitate and alleviate medical conditions and diseases unique to cancer patients
- Enhance skills in conducting clinical research
- Strengthen communication skills by presenting formal and informal lectures, writing a professional manuscript, and leading interdisciplinary discussions
The PGY-2 oncology residency provides opportunities for advanced training in all areas related to cancer. During each learning experience, residents work closely with their preceptors, highly qualified pharmacists, oncology physicians and other allied health care professionals.
The PGY-2 Pharmacy Residency in Oncology at Mayo Clinic Hospital — Rochester was accredited by the American Society of Health-System Pharmacists (ASHP) in 2003 and has produced respected clinicians who practice across the U.S. The residency program is continuously evaluated for improvement opportunities to ensure graduates make a seamless transition into clinical practice. One candidate a year is selected on a competitive basis.
Preceptors for the PGY-2 oncology residency provide direct patient care in virtually every specialty area and are actively involved in resident teaching and other scholarly activities. The preceptors come from diverse backgrounds and share numerous years of experience, clinical knowledge and research interests. Residents have direct access to preceptors and mentors to optimize the learning experience.
More than 100 pharmacists at Mayo Clinic are certified by the Board of Pharmacy Specialties in various practice areas. All residency program preceptors meet the qualifications outlined by the ASHP.
Mayo Clinic Cancer Center is a National Cancer Institute-designated comprehensive cancer center with an international presence. More than 135,000 people receive cancer treatment at Mayo Clinic each year, making it one of the largest cancer treatment facilities in the nation. Hundreds of clinical trials led by Mayo Clinic physicians and scientists are available for patients, including trials through the Alliance for Clinical Trials in Oncology, Phase I Program, Phase II Consortium and Cancer Prevention Network.
Additional trials are available through cooperative research affiliations and collaborations with the National Cancer Institute and other clinical trial groups. Training for this residency is primarily conducted at Mayo Clinic Hospital — Rochester, though students may have learning experiences at Mayo Clinic's outpatient complex.